AlphaFold Changed Drug Discovery. What Comes Next for South Asia?

AlphaFold solved the protein structure prediction problem that biologists had worked on for 50 years. DeepMind's 2020 breakthrough, confirmed at CASP14, was not incremental progress — it was the problem being solved. The protein data bank now contains over 200 million predicted structures. Every protein in every known organism.

This is a genuine scientific achievement. It belongs on the short list of things AI has demonstrably changed about how science is done.

The question for ASI Research Lab is what comes next, specifically in the context of South Asian diseases.

Where AlphaFold has had limited impact

Drug discovery for neglected tropical diseases has not meaningfully accelerated since AlphaFold's release. The reason is not scientific — it is economic. AlphaFold solves the protein structure prediction step. The subsequent steps — identifying druggable binding sites, screening compound libraries, validating hits in clinical populations — still require investment and researchers focused on that disease area.

For dengue, malaria, and thalassemia, the structural biology data is now available. The disease mechanisms are relatively well understood. The bottleneck has shifted from "we don't understand the protein structure" to "no large pharmaceutical company has sufficient financial incentive to fund clinical trials for diseases that primarily affect low-income populations."

The research opportunity

ASI Research Lab's medical research mandate includes AI-assisted drug discovery for South Asian endemic diseases. The approach is not to compete with large pharmaceutical companies in compound synthesis — we are a research lab, not a drug manufacturer. The approach is:

1. Use AlphaFold structural predictions for dengue NS5 polymerase, PfCRT (malaria chloroquine resistance transporter), and beta-globin variants (thalassemia)
2. Apply graph neural network models to identify potential binding sites not previously characterized
3. Screen existing approved compound databases (FDA, EMA) for repurposing candidates using docking simulation
4. Publish findings with open access — the research output has more value as a public good than as a protected IP asset

Drug repurposing — finding new therapeutic applications for approved compounds — is particularly tractable for a research lab without clinical trial capacity. The safety profile of approved drugs is known. The regulatory path for repurposing is shorter. The structural predictions from AlphaFold make the computational screening step feasible at low cost.

The target: December 2026

The first published research output from Monolith 02 targets December 2026. The scope for that first paper is deliberately narrow: a computational analysis of binding site predictions for dengue NS5 polymerase using AlphaFold-generated structures, cross-referenced with existing compound databases.

This is not a cure. It is a contribution to the scientific record that did not exist before ASI Research Lab existed. It is the kind of contribution that South Asia's medical AI landscape needs — and that the Western AI labs doing the most advanced work have no incentive to produce.